Skip to main content
Top
Published in: International Journal of Hematology 6/2020

01-06-2020 | Thrombosis | Original Article

Comparison of clinical phenotype with genetic and laboratory results in 31 patients with congenital dysfibrinogenemia in northern Slovakia

Authors: Tomas Simurda, Jana Zolkova, Zuzana Kolkova, Dusan Loderer, Miroslava Dobrotova, Ingrid Skornova, Monika Brunclíkova, Marian Grendar, Zora Lasabova, Jan Stasko, Peter Kubisz

Published in: International Journal of Hematology | Issue 6/2020

Login to get access

Abstract

Congenital dysfibrinogenemia (CD) is a rare disorder of hemostasis. The majority of cases are caused by heterozygous missense mutations in one of the three fibrinogen genes. Patients with CD may experience bleeding and thrombosis, but many are asymptomatic. To better describe the clinical, laboratory, and genotypic picture of CD, we evaluated 31 patients from seven unrelated families using standard coagulation tests and genetic analysis. The clinical phenotype consisted of bleeding in 13/31 (42%) patients; other patients (18/31; 58%) were asymptomatic. Among patients with bleeding, symptoms were mostly in single anatomical sites, with variable intensity of bleeding. Compared to results from a previous large systematic survey, our results showed a similar mean bleeding score, but a higher incidence of bleeding episodes without thrombotic complications. In the present study, we identified three known pathogenic point mutations in the FGA (c.95G > A, c.104G > A) and FGB (c.586C > T) genes. The variants of CD identified in this cross-sectional study were either asymptomatic or had bleeding manifestations and showed similar laboratory features, irrespective of genotype. Results from genetic and clinical studies will continue to yield valuable information on the structure and function of the fibrinogen molecule.
Literature
1.
go back to reference Simurda T, Snahnicanova Z, Loderer D, Sokol J, Stasko J, Lasbova Z, et al. fibrinogen martin: a novel mutation in FGB (GLN180STOP) causing congenital afibrinogenemia. Semin Thromb Hemost. 2016;42:455–8.PubMedCrossRef Simurda T, Snahnicanova Z, Loderer D, Sokol J, Stasko J, Lasbova Z, et al. fibrinogen martin: a novel mutation in FGB (GLN180STOP) causing congenital afibrinogenemia. Semin Thromb Hemost. 2016;42:455–8.PubMedCrossRef
2.
go back to reference Asselta R, Platè M, Robusto M, Borhany M, Guella I, Soldà G, et al. Clinical and molecular characterisation of 21 patients affected by quantitative fibrinogen deficiency. Thromb Haemost. 2015;113:567–76.PubMedCrossRef Asselta R, Platè M, Robusto M, Borhany M, Guella I, Soldà G, et al. Clinical and molecular characterisation of 21 patients affected by quantitative fibrinogen deficiency. Thromb Haemost. 2015;113:567–76.PubMedCrossRef
3.
go back to reference de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost. 2013;39:585–95.PubMedCrossRef de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost. 2013;39:585–95.PubMedCrossRef
4.
go back to reference Cieśla M, Adamczyk Z, Barbasz J, Wasilewska M. Mechanisms of fibrinogen adsorption at solid substrates at lower pH. Langmuir. 2013;11(29):7005–166.CrossRef Cieśla M, Adamczyk Z, Barbasz J, Wasilewska M. Mechanisms of fibrinogen adsorption at solid substrates at lower pH. Langmuir. 2013;11(29):7005–166.CrossRef
5.
go back to reference Platé M, Asselta R, Peyvandi F, Tenchini ML, Duga S. Molecular characterization of the first missense mutation in the fibrinogen Aalpha-chain gene identified in a compound heterozygous afibrinogenemic patient. Biochim Biophys Acta. 2007;1772:781–7.PubMedCrossRef Platé M, Asselta R, Peyvandi F, Tenchini ML, Duga S. Molecular characterization of the first missense mutation in the fibrinogen Aalpha-chain gene identified in a compound heterozygous afibrinogenemic patient. Biochim Biophys Acta. 2007;1772:781–7.PubMedCrossRef
6.
go back to reference Casini A, Blondon M, Tintillier V, Goodyer M, Sezgin ME, Gunes AM, et al. Mutational epidemiology of congenital fibrinogen disorders. Thromb Haemost. 2018;118:1867–74.PubMedCrossRef Casini A, Blondon M, Tintillier V, Goodyer M, Sezgin ME, Gunes AM, et al. Mutational epidemiology of congenital fibrinogen disorders. Thromb Haemost. 2018;118:1867–74.PubMedCrossRef
7.
go back to reference Simurda T, Zolkova J, Snahnicanova Z, Loderer D, Skornova I, Sokol J, et al. Identification of two novel fibrinogen Bβ chain mutations in two Slovak families with quantitative fibrinogen disorders. Int J Mol Sci. 2017;19:100.PubMedCentralCrossRef Simurda T, Zolkova J, Snahnicanova Z, Loderer D, Skornova I, Sokol J, et al. Identification of two novel fibrinogen Bβ chain mutations in two Slovak families with quantitative fibrinogen disorders. Int J Mol Sci. 2017;19:100.PubMedCentralCrossRef
8.
go back to reference Zhou J, Zhu P, Zhang X. A Chinese family with congenital dysfibrinogenemia carries a heterozygous missense mutation in FGA: concerning the genetic abnormality and clinical treatment. Pak J Med Sci. 2017;33:968–72.PubMedPubMedCentral Zhou J, Zhu P, Zhang X. A Chinese family with congenital dysfibrinogenemia carries a heterozygous missense mutation in FGA: concerning the genetic abnormality and clinical treatment. Pak J Med Sci. 2017;33:968–72.PubMedPubMedCentral
9.
go back to reference Blombäck M, Blombäck B, Mammen EF. Fibrinogen Detroit—a molecular defect in the N-terminal disulphide knot of human fibrinogen? Nature. 1968;218:134–7.PubMedCrossRef Blombäck M, Blombäck B, Mammen EF. Fibrinogen Detroit—a molecular defect in the N-terminal disulphide knot of human fibrinogen? Nature. 1968;218:134–7.PubMedCrossRef
10.
go back to reference Miesbach W, Galanakis D, Scharrer I. Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. Blood Coagul Fibrinolysis. 2009;20:366–70.PubMedCrossRef Miesbach W, Galanakis D, Scharrer I. Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. Blood Coagul Fibrinolysis. 2009;20:366–70.PubMedCrossRef
11.
go back to reference Simurda T, Dobrotova M, Skornova I, Zolkova J, Plamenova I, Ivankova J, et al. Congenital dysfibrinogenemia—laboratory diagnostics and treatment approaches. Vask Med. 2018;10:90–3. Simurda T, Dobrotova M, Skornova I, Zolkova J, Plamenova I, Ivankova J, et al. Congenital dysfibrinogenemia—laboratory diagnostics and treatment approaches. Vask Med. 2018;10:90–3.
12.
go back to reference Simurda T, Kubisz P, Dobrotova M, Neca L, Stasko J. Perioperative coagulation management in a patient with congenital afibrinogenemia during revision total hip arthroplasty. Semin Thromb Hemost. 2016;42:689–92.PubMedCrossRef Simurda T, Kubisz P, Dobrotova M, Neca L, Stasko J. Perioperative coagulation management in a patient with congenital afibrinogenemia during revision total hip arthroplasty. Semin Thromb Hemost. 2016;42:689–92.PubMedCrossRef
13.
go back to reference Casini A, Neerman-Arbez M, Ariëns RA, de Moerloose P. Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. J Thromb Haemost. 2015;13:909–19.PubMedCrossRef Casini A, Neerman-Arbez M, Ariëns RA, de Moerloose P. Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. J Thromb Haemost. 2015;13:909–19.PubMedCrossRef
14.
go back to reference Luo M, Deng D, Xiang L, Cheng P, Liao L, Deng X, et al. Three cases of congenital dysfibrinogenemia in unrelated Chinese families: heterozygous missense mutation in fibrinogen alpha chain Argl6His. Medicine (Baltimore). 2016;95:4864.CrossRef Luo M, Deng D, Xiang L, Cheng P, Liao L, Deng X, et al. Three cases of congenital dysfibrinogenemia in unrelated Chinese families: heterozygous missense mutation in fibrinogen alpha chain Argl6His. Medicine (Baltimore). 2016;95:4864.CrossRef
15.
go back to reference Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8:2063–5.PubMedCrossRef Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8:2063–5.PubMedCrossRef
16.
18.
go back to reference Shapiro SE. Diagnosis and management of dysfibrinogenemia. Clin Adv Hematol Oncol. 2018;16:602–5.PubMed Shapiro SE. Diagnosis and management of dysfibrinogenemia. Clin Adv Hematol Oncol. 2018;16:602–5.PubMed
20.
go back to reference Miesbach W, Scharrer I, Henschen A, Neerman-Arbez M, Spitzer S, Galanakis D. Inherited dysfibrinogenemia: clinical phenotypes associated with five different fibrinogen structure defects. Blood Coagul Fibrinolysis. 2010;21:35–40.PubMedCrossRef Miesbach W, Scharrer I, Henschen A, Neerman-Arbez M, Spitzer S, Galanakis D. Inherited dysfibrinogenemia: clinical phenotypes associated with five different fibrinogen structure defects. Blood Coagul Fibrinolysis. 2010;21:35–40.PubMedCrossRef
21.
go back to reference Casini A, Blondon M, Lebreton A, Koegel J, Tintillier V, de Maistre E, et al. Natural history of patients with congenital dysfibrinogenemia. Blood. 2015;125:553–61.PubMedPubMedCentralCrossRef Casini A, Blondon M, Lebreton A, Koegel J, Tintillier V, de Maistre E, et al. Natural history of patients with congenital dysfibrinogenemia. Blood. 2015;125:553–61.PubMedPubMedCentralCrossRef
22.
go back to reference Shapiro SE, Phillips E, Manning RA, Morse CV, Murden SL, Laffan MA, et al. Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia. Br J Haematol. 2013;160:220–7.PubMedCrossRef Shapiro SE, Phillips E, Manning RA, Morse CV, Murden SL, Laffan MA, et al. Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia. Br J Haematol. 2013;160:220–7.PubMedCrossRef
23.
go back to reference Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia report on a study of the SSC subcommittee on fibrinogen. Thromb Haemost. 1995;73:151–61.PubMedCrossRef Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia report on a study of the SSC subcommittee on fibrinogen. Thromb Haemost. 1995;73:151–61.PubMedCrossRef
24.
go back to reference Casini A, de Moerloose P, Neerman-Arbez M. Clinical features and management of congenital fibrinogen deficiencies. Semin Thromb Hemost. 2016;42:366–74.PubMedCrossRef Casini A, de Moerloose P, Neerman-Arbez M. Clinical features and management of congenital fibrinogen deficiencies. Semin Thromb Hemost. 2016;42:366–74.PubMedCrossRef
25.
go back to reference de Moerloose P, Boehlen F, Neerman-Arbez M. Fibrinogen and the risk of thrombosis. Semin Thromb Hemost. 2010;36:7–17.PubMedCrossRef de Moerloose P, Boehlen F, Neerman-Arbez M. Fibrinogen and the risk of thrombosis. Semin Thromb Hemost. 2010;36:7–17.PubMedCrossRef
27.
go back to reference Lebreton A, Casini A. Diagnosis of congenital fibrinogen disorders. Ann Biol Clin (Paris). 2016;74:405–12. Lebreton A, Casini A. Diagnosis of congenital fibrinogen disorders. Ann Biol Clin (Paris). 2016;74:405–12.
28.
go back to reference Miesbach W, Schenk J, Alesci S, Lindhoff-Last E. Comparison of the fibrinogen clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia. Thromb Res. 2010;126:428–33.CrossRef Miesbach W, Schenk J, Alesci S, Lindhoff-Last E. Comparison of the fibrinogen clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia. Thromb Res. 2010;126:428–33.CrossRef
29.
go back to reference Neerman-Arbez M, de Moerloose P, Casini A. Laboratory and genetic investigation of mutations accounting for congenital fibrinogen disorders. Semin Thromb Hemost. 2016;42:356–65.PubMedCrossRef Neerman-Arbez M, de Moerloose P, Casini A. Laboratory and genetic investigation of mutations accounting for congenital fibrinogen disorders. Semin Thromb Hemost. 2016;42:356–65.PubMedCrossRef
30.
go back to reference Lefkowitz JB, DeBoom T, Weller A, Clarke S, Lavrinets D. Fibrinogen Longmont: a dysfibrinogenemia that causes prolonged clot-based test results only when using an optical detection method. Am J Hematol. 2000;63:149–55.PubMedCrossRef Lefkowitz JB, DeBoom T, Weller A, Clarke S, Lavrinets D. Fibrinogen Longmont: a dysfibrinogenemia that causes prolonged clot-based test results only when using an optical detection method. Am J Hematol. 2000;63:149–55.PubMedCrossRef
31.
go back to reference Casini A, Undas A, Palla R, et al. Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH. J Thromb Haemost. 2018;1(6):1887–900.CrossRef Casini A, Undas A, Palla R, et al. Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH. J Thromb Haemost. 2018;1(6):1887–900.CrossRef
32.
go back to reference Paraboschi EM, Duga S, Asselta R. Fibrinogen as a pleiotropic protein causing human diseases: the mutational burden of Aα, Bβ, and γ chains. Int J Mol Sci. 2017;18:2711.PubMedCentralCrossRef Paraboschi EM, Duga S, Asselta R. Fibrinogen as a pleiotropic protein causing human diseases: the mutational burden of Aα, Bβ, and γ chains. Int J Mol Sci. 2017;18:2711.PubMedCentralCrossRef
33.
go back to reference Asselta R, Robusto M, Platé M, Santoro C, Peyvandi F, Duga S. Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylation. Thromb Res. 2015;136:168–74.PubMedCrossRef Asselta R, Robusto M, Platé M, Santoro C, Peyvandi F, Duga S. Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylation. Thromb Res. 2015;136:168–74.PubMedCrossRef
34.
go back to reference Tiscia GL, Margaglione M. Human fibrinogen: molecular and genetic aspects of congenital disorders. Int J Mol Sci. 2018;19:1597.PubMedCentralCrossRef Tiscia GL, Margaglione M. Human fibrinogen: molecular and genetic aspects of congenital disorders. Int J Mol Sci. 2018;19:1597.PubMedCentralCrossRef
35.
go back to reference Batorova A, Jankovicova D, Lazur J, et al. Vrodena dysfibrinogenemia a hypofibrinogenemia—molekulova baza a klinicky fenotyp. Interna medicina. 2016;16:109–15. Batorova A, Jankovicova D, Lazur J, et al. Vrodena dysfibrinogenemia a hypofibrinogenemia—molekulova baza a klinicky fenotyp. Interna medicina. 2016;16:109–15.
37.
go back to reference Kadir R, Chi C, Bolton-Maggs P. Pregnancy and rare bleeding disorders. Haemophilia. 2009;15:990–1005.PubMedCrossRef Kadir R, Chi C, Bolton-Maggs P. Pregnancy and rare bleeding disorders. Haemophilia. 2009;15:990–1005.PubMedCrossRef
38.
go back to reference Kotlin R, Zichová K, Suttnar J, Reicheltová Z, Salaj P, Hrachovinová I, et al. Congenital dysfibrinogenemia Aα Gly13Glu associated with bleeding during pregnancy. Thromb Res. 2011;127:277–8.PubMedCrossRef Kotlin R, Zichová K, Suttnar J, Reicheltová Z, Salaj P, Hrachovinová I, et al. Congenital dysfibrinogenemia Aα Gly13Glu associated with bleeding during pregnancy. Thromb Res. 2011;127:277–8.PubMedCrossRef
39.
go back to reference Gaja A, Terasawa F, Okumuna N. Hereditární dysfibrinogenemie s Aa13Gly%3eGlu mutací. In: Malý M, Pecka J, editors. Trombóza a hemostáza. HK Credit: Hradec Králové; 2001. p. 114. Gaja A, Terasawa F, Okumuna N. Hereditární dysfibrinogenemie s Aa13Gly%3eGlu mutací. In: Malý M, Pecka J, editors. Trombóza a hemostáza. HK Credit: Hradec Králové; 2001. p. 114.
40.
go back to reference Asselta R, Duga S, Spena S, D'Angelo F, Casetta B, Papa ML, et al. Congenital afibrinogenemia: mutations leading to premature termination codons in fibrinogen Aα-chain gene are not associated with the decay of the mutant mRNAs. Blood. 2001;98:3685–92.PubMedCrossRef Asselta R, Duga S, Spena S, D'Angelo F, Casetta B, Papa ML, et al. Congenital afibrinogenemia: mutations leading to premature termination codons in fibrinogen Aα-chain gene are not associated with the decay of the mutant mRNAs. Blood. 2001;98:3685–92.PubMedCrossRef
41.
go back to reference Yan J, Luo M, Cheng P, Liao L, Deng X, Deng D, et al. A novel mutation in the fibrinogen Aα chain (Gly13Arg, fibrinogen Nanning) causes congenital dysfibrinogenemia associated with defective peptide A release. Int J Hematol. 2017;105:506–14.PubMedCrossRef Yan J, Luo M, Cheng P, Liao L, Deng X, Deng D, et al. A novel mutation in the fibrinogen Aα chain (Gly13Arg, fibrinogen Nanning) causes congenital dysfibrinogenemia associated with defective peptide A release. Int J Hematol. 2017;105:506–14.PubMedCrossRef
42.
go back to reference Mathonnet F, Peltier JY, Detruit H, de Raucourt E, Alvarez JC, Mazmanian GM, et al. Fibrinogen Saint-Germain I: a case of the heterozygous Aalpha GLY 12→ VAL fibrinogen variant. Blood Coagul Fibrinolysis. 2002;13:149–53.PubMedCrossRef Mathonnet F, Peltier JY, Detruit H, de Raucourt E, Alvarez JC, Mazmanian GM, et al. Fibrinogen Saint-Germain I: a case of the heterozygous Aalpha GLY 12→ VAL fibrinogen variant. Blood Coagul Fibrinolysis. 2002;13:149–53.PubMedCrossRef
43.
go back to reference Lounes KC, Lefkowitz JB, Henschen-Edman AH, Coates AI, Hantgan RR, Lord ST. The impaired polymerization of fibrinogen Longmont (Bbeta166Arg→ Cys) is not improved by removal of disulfide-linked dimers from a mixture of dimers and cysteine-linked monomers. Blood. 2001;98:661–6.PubMedCrossRef Lounes KC, Lefkowitz JB, Henschen-Edman AH, Coates AI, Hantgan RR, Lord ST. The impaired polymerization of fibrinogen Longmont (Bbeta166Arg→ Cys) is not improved by removal of disulfide-linked dimers from a mixture of dimers and cysteine-linked monomers. Blood. 2001;98:661–6.PubMedCrossRef
44.
go back to reference van Vulpen LFD, Amin SN, Makris M. Severe wound healing impairment in a patient with dysfibrinogenaemia. Thromb Haemost. 2018;118:430–2.PubMedCrossRef van Vulpen LFD, Amin SN, Makris M. Severe wound healing impairment in a patient with dysfibrinogenaemia. Thromb Haemost. 2018;118:430–2.PubMedCrossRef
45.
go back to reference Liao Z, Tang H, Xie Y, Duan X, Xu S, Liu C, et al. Fibrinogen hangzhou: congenital dysfibrinogenemia caused by the novel missense mutation in FGG (γ308Asn→Thr). Clin Chim Acta. 2014;428:106–9.PubMedCrossRef Liao Z, Tang H, Xie Y, Duan X, Xu S, Liu C, et al. Fibrinogen hangzhou: congenital dysfibrinogenemia caused by the novel missense mutation in FGG (γ308Asn→Thr). Clin Chim Acta. 2014;428:106–9.PubMedCrossRef
46.
go back to reference Santacroce R, Cappucci F, Pisanelli D, Perricone F, Papa ML, Santoro R, et al. Inherited abnormalities of fibrinogen: 10-year clinical experience of an Italian group. Blood Coagul Fibrinolysis. 2006;17:235–40.PubMedCrossRef Santacroce R, Cappucci F, Pisanelli D, Perricone F, Papa ML, Santoro R, et al. Inherited abnormalities of fibrinogen: 10-year clinical experience of an Italian group. Blood Coagul Fibrinolysis. 2006;17:235–40.PubMedCrossRef
Metadata
Title
Comparison of clinical phenotype with genetic and laboratory results in 31 patients with congenital dysfibrinogenemia in northern Slovakia
Authors
Tomas Simurda
Jana Zolkova
Zuzana Kolkova
Dusan Loderer
Miroslava Dobrotova
Ingrid Skornova
Monika Brunclíkova
Marian Grendar
Zora Lasabova
Jan Stasko
Peter Kubisz
Publication date
01-06-2020
Publisher
Springer Singapore
Published in
International Journal of Hematology / Issue 6/2020
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-020-02842-9

Other articles of this Issue 6/2020

International Journal of Hematology 6/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine